GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pear Therapeutics Inc (OTCPK:PEARQ) » Definitions » Other Net Income (Loss)

Pear Therapeutics (Pear Therapeutics) Other Net Income (Loss) : $0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Pear Therapeutics Other Net Income (Loss)?

Pear Therapeutics's Other Net Income (Loss) for the three months ended in Dec. 2022 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.


Pear Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for Pear Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pear Therapeutics Other Net Income (Loss) Chart

Pear Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Other Net Income (Loss)
- - - -

Pear Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pear Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pear Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Pear Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pear Therapeutics (Pear Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 State Street, 13th Floor, Boston, MA, USA, 02109
Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.
Executives
5am Partners Iv, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Erin K. Brenner officer: Chief Product Dev. Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Julia Strandberg officer: Chief Commercial Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ronan O'brien officer: General Counsel & Secretary C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Mccann Corey director, officer: President and CEO C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Yuri Maricich officer: Chief Medical Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ellen Snow officer: Chief Accounting Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Christopherd T Guiffre officer: CFO, COO, Treas., & Asst. Sec. 65 HAYDEN AVE, LEXINGTON MA 02421
Katherine Jeffery officer: Chief People Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Paul Mango director C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Timothy A Wicks director C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239
Shivakumar Rajaraman director 6260 LOOKOUT ROAD, BOULDER CO 80301
Klp Spac 1 Llc 10 percent owner 195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510
Zack Lynch director C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Elbrus Investments Pte. Ltd. 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891

Pear Therapeutics (Pear Therapeutics) Headlines